Artificial intelligence and open science in discovery of disease-modifying medicines for Alzheimer’s disease
Year: 2024
Type: review
Abstract: The high failure rate of clinical trials in Alzheimer's disease (AD) and AD-related dementia (ADRD) is due to a lack of understanding of the pathophysiology of disease, and this deficit may be addressed by applying artificial intelligence (AI) to "big data" to rapidly and effectively expand therapeutic development efforts. Recent accelerations in computing power and availability of big data, including electronic health records and multi-omics profiles, have converged to provide opportunities for scientific discovery and treatment development. Here, we review the potential utility of applying AI approaches to big data for discovery of disease-modifying medicines for AD/ADRD. We illustrate how AI tools can be applied to the AD/ADRD drug development pipeline through collaborative efforts among neurologists, gerontologists, geneticists, pharmacologists, medicinal chemists, and computational scientists. AI and open data science expedite drug discovery and development of disease-modifying therapeutics for AD/ADRD and other neurodegenerative diseases.
Source: Cell Reports Medicine
Institutions: Cleveland Clinic, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic Research, Case Western Reserve University, Cornell University, Weill Cornell Medicine, HEC Montréal, Mila - Quebec Artificial Intelligence Institute, Northeast Ohio Medical University, Indiana University Indianapolis, Lou Ruvo Brain Institute, IBM (United States), Hebrew University of Jerusalem, IBM Research - Haifa, University Hospitals of Cleveland, University Hospitals Cleveland Medical Center, Louis Stokes Cleveland VA Medical Center, University of Nevada, Las Vegas
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $5,460
Funders: Center for Cancer Research, U.S. Department of Health and Human Services, U.S. Department of Veterans Affairs, Alzheimer's Association, American Heart Association, Alzheimer's Drug Discovery Foundation, Case Western Reserve University, Government of South Australia, Novo Nordisk, National Institutes of Health, GE Healthcare, National Institute on Aging, National Cancer Institute, National Institute of General Medical Sciences, National Institute of Neurological Disorders and Stroke, NIH Clinical Center
Awards: Multimodal single-cell genomic and epigenomic analyses elucidate Alzheimer’s sexual dimorphism in human immune systems aging, The Alzheimer Disease Sequence Analysis Collaborative, Linking tau proteostasis with neuronal activity in FTD, Post-Acute Sequelae of SARS-CoV-2 Infection and Subsequent Disease Progression in Individuals with AD/ADRD: Influence of the Social and Environmental Determinants of Health, Chronic Traumatic Encephalopathy: Detection, Diagnosis, Course, and Risk Factors, Endophenotype Network-based Approaches to Prediction and Population-based Validation of in Silico Drug Repurposing for Alzheimers Disease, Global Alzheimer's Platform Trial-Ready Cohort for Preclinical/Prodromal Alzheimer's Disease, Alzheimer's Disease and Related Dementia-like Sequelae of SARS-CoV-2 Infection: Virus-Host Interactome, Neuropathobiology, and Drug Repurposing, G5036105457, Identification of Mild Cognitive Impairment using Machine Learning from Language and Behavior Markers, Precision Medicine Digital Twins for Alzheimer’s Target and Drug Discovery and Longevity, G597722628, G6012682559, G6336093431, G7148773069, Dark GPCR signaling underlying the Microbiome-Gut-Brain Axis for Alzheimer's Disease and Related Dementia, nvestigating the role of neuroinflammation in Limbic-predominant age related TDP43 encephalopathy, G8356492347, G8422249695, G8478589385, HEI C AND MORPHOGENESIS AND SIGNALING, Tau acetylation in Alzheimer's disease, G8844755871, G8882569155, Renewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2) CNTN - Resubmission, Microglial Activation and Inflammatory Endophenotypes Underlying Sex Differences of Alzheimer’s Disease, Eligibility criteria design for Alzheimer's trials with real-world data and explainable AI, Neuroprotective actions of cystathionine g-lyase through gasotransmitter hydrogen sulfide signaling, Disparities of Alzheimer's disease progression in sexual and gender minorities, Cleveland Alzheimers Disease Research Center, Dementia with Lewy Bodies Consortium, Characterize neuronal and glial cell-specific vulnerability to proteinopathies in Alzheimer's disease using multimodal single-nuclei genomic and epigenomic approaches, Alzheimer's Disease and Related Dementias Innovation Incubator (InnovaTor), Chemical, Structural and Cell-Signaling Interrogation of 15-Prostanglandin Dehydrogenase in Tissue Repair and Regeneration, TREM2 Genotype-Informed Drug Repurposing and Combination Therapy Design for Alzheimers Disease, Computational Drug Repurposing for AD/ADRD with Integrative Analysis of Real World Data and Biomedical Knowledge, Alzheimer's Clinical Trial InnOvatioN (ACTION) Initiative, South Texas Alzheimer's Disease Center, Alzheimer's MultiOme Data Repurposing: Artificial Intelligence, Network Medicine, and Therapeutics Discovery
OpenAlex ID: W4391985998
